RESUMEN
Reaction of heterometallic cubane-type cluster complexes-[Mo3{Pd(dba)}S4Cl3(dbbpy)3]PF6, [Mo3{Pd(tu)}S4Cl3(dbbpy)3]Cl and [Mo3{Pd(dba)}S4(acac)3(py)3]PF6, where dba-dibenzylideneacetone, dbbpy-4,4'-di-tert-butyl-2,2'-bipyridine, tu-thiourea, acac-acetylacetonate, py-pyridine, with white phosphorus (P4) in the presence of water leads to the formation of phosphorous acid H3PO3 as the major product. The crucial role of the Pd atom in the cluster core {Mo3PdS4} has been established in the hydrolytic activation of P4 molecule. The main intermediate of the process, the cluster complex [Mo3{PdP(OH)3}S4Cl3(dbbpy)3]+ with coordinated P(OH)3 molecule and phosphine PH3, have been detected by 31P NMR spectroscopy in the reaction mixture.
Asunto(s)
Molibdeno/química , Compuestos Organometálicos/química , Paladio/química , Fósforo/química , HidrólisisRESUMEN
Carbonic anhydrase isoenzyme VI (CA VI) plays an important role in the homeostasis of oral tissues participating in the processes of taste, protection of dental tissues against the loss of minerals, caries, and possibly in the formation of dental calculus in periodontal disease. This study aimed to verify the correlation between changes in the expression and activity of human salivary carbonic anhydrase VI and genetic polymorphisms in its gene (CA6). The study population consisted of 182 healthy volunteers (female and male, aged 18-22). Samples of total saliva were assayed for CA VI concentrations using a specific time-resolved immunofluorometric assay. CA VI catalytic activity was detected by a modified protocol of Kotwica et al. [J Physiol Pharmacol 2006;57(suppl 8):107-123], adapted to CA VI in saliva. Samples of genomic DNA were genotyped for polymorphisms rs2274327 (C/T), rs2274328 (A/C) and rs2274333 (A/G) by TaqMan® SNP Genotyping Assays. The concentration and catalytic activity of the salivary CA VI obtained for the different genotypes were analyzed using the Kruskal-Wallis nonparametric test and the Dunn test. The results showed that individuals with TT genotype (rs2274327) had significantly lower CA VI concentrations than the individuals with genotypes CT or CC (p < 0.05). There was also an association between polymorphism rs2274333 and salivary CA VI concentrations. There were no associations between the three polymorphisms analyzed and variations in CA VI activity. Our results suggest that polymorphisms in the CA6 gene are associated with the concentrations of secreted CA VI.
Asunto(s)
Anhidrasas Carbónicas/genética , Polimorfismo Genético/genética , Proteínas y Péptidos Salivales/genética , Adenina , Adolescente , Alelos , Biocatálisis , Anhidrasas Carbónicas/análisis , Citosina , Femenino , Frecuencia de los Genes/genética , Genotipo , Guanina , Humanos , Desequilibrio de Ligamiento/genética , Masculino , Familia de Multigenes/genética , Polimorfismo de Nucleótido Simple/genética , Saliva/enzimología , Proteínas y Péptidos Salivales/análisis , Timina , Adulto JovenRESUMEN
PURPOSE: To examine heart disease in the systemic lupus erythematosus (SLE) and the association of cardiac abnormalities with anticardiolipin antibodies (ACL). METHODS: Sixteen patients with active SLE disease (group I) were compared with 14 patients without disease activity (group II). A control group of 10 healthy subjects were also evaluated. Patients were subjected to cardiovascular history and physical examination as well as electrocardiogram, thoracic x-ray, two-dimensional and Doppler echocardiogram, and ACL serum determination (ELISA). RESULTS: Myocardial disease characterized by tachycardia, heart failure or echocardiographic abnormalities was shown by 75% of patients in the group I. It was associated with ACL positive in 27.2% of these patients. Pericardial and valvular involvement were observed in 25% of patients in group I. Group II showed myocardial involvement in 21.4% of patients without positive ACL. CONCLUSION: Myocardial disease was the most frequent heart involvement in active SLE, and we did not found any association between SLE heart disease and positive anticardiolipin antibodies.